Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Product description Product information

Access and distribution

3 evidence topics · 5 sources

Manufacturing and commercial readiness

“GMP manufacturing facility in San Diego is operational” (opens the source at this quote in a new tab)
“Capricor is advancing commercial readiness at a slower pace pending regulatory clarity.” (opens the source at this quote in a new tab)

Patient support and access planning

“Planning is underway across all critical launch functions, including patient support, market access, reimbursement planning, medical affairs and physician education.” (opens the source at this quote in a new tab)

Distribution agreement

“Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of Deramiocel for the treatment of DMD.” (opens the source at this quote in a new tab)

“The Company seeks rescission of the U.S. Distribution Agreement” (opens the source at this quote in a new tab)

“Today, the New Jersey state court granted Capricor’s request to pursue its case through arbitration.” (opens the source at this quote in a new tab)